TY - JOUR
T1 - Omics-based identification of the combined effects of idiosyncratic drugs and inflammatory cytokines on the development of drug-induced liver injury
AU - Jiang, Jian
AU - Mathijs, K
AU - Timmermans, L
AU - Claessen, S M
AU - Hecka, A
AU - Weusten, J
AU - Peters, R
AU - van Delft, J H
AU - Kleinjans, J C S
AU - Jennen, D G J
AU - de Kok, T M
N1 - Copyright © 2017 Elsevier Inc. All rights reserved.
PY - 2017/10/1
Y1 - 2017/10/1
N2 - The mechanisms of idiosyncratic drug-induced hepatotoxicity remain largely unclear. It has demonstrated that the drug idiosyncrasy is potentiated in the context of inflammation and intracellular ceramides may play a role in this process. To study the mechanisms, HepG2 cells were co-treated with high and low doses of three idiosyncratic (I) and three non-idiosyncratic (N) compounds, with (I+ and N+) or without (I- and N-) a cytokine mix. Microarray, lipidomics and flow cytometry were performed to investigate the genome-wide expression patterns, the intracellular ceramide levels and the induction of apoptosis. We found that all I+ treatments significantly influenced the immune response- and response to stimulus-associated gene ontology (GO) terms, but the induction of apoptotic pathways, which was confirmed by flow cytometry, only appeared to be induced after the high-dose treatment. The ceramide signaling-, ER stress-, NF-kB activation- and mitochondrial activity-related pathways were biologically involved in apoptosis induced by the high-dose I+. Additionally, genes participating in ceramide metabolism were significantly altered resulting in a measurable increase in ceramide levels. The increases in ceramide concentrations may induce ER stress and activate the JNK pathway by affecting the expression of the related genes, and eventually trigger the mitochondria-independent apoptosis in hepatocytes. Overall, our study provides a potential mechanism to explain the role of inflammation in idiosyncratic drug reactions.
AB - The mechanisms of idiosyncratic drug-induced hepatotoxicity remain largely unclear. It has demonstrated that the drug idiosyncrasy is potentiated in the context of inflammation and intracellular ceramides may play a role in this process. To study the mechanisms, HepG2 cells were co-treated with high and low doses of three idiosyncratic (I) and three non-idiosyncratic (N) compounds, with (I+ and N+) or without (I- and N-) a cytokine mix. Microarray, lipidomics and flow cytometry were performed to investigate the genome-wide expression patterns, the intracellular ceramide levels and the induction of apoptosis. We found that all I+ treatments significantly influenced the immune response- and response to stimulus-associated gene ontology (GO) terms, but the induction of apoptotic pathways, which was confirmed by flow cytometry, only appeared to be induced after the high-dose treatment. The ceramide signaling-, ER stress-, NF-kB activation- and mitochondrial activity-related pathways were biologically involved in apoptosis induced by the high-dose I+. Additionally, genes participating in ceramide metabolism were significantly altered resulting in a measurable increase in ceramide levels. The increases in ceramide concentrations may induce ER stress and activate the JNK pathway by affecting the expression of the related genes, and eventually trigger the mitochondria-independent apoptosis in hepatocytes. Overall, our study provides a potential mechanism to explain the role of inflammation in idiosyncratic drug reactions.
KW - Apoptosis/drug effects
KW - Ceramides/metabolism
KW - Chemical and Drug Induced Liver Injury/metabolism
KW - Cytokines/metabolism
KW - Dose-Response Relationship, Drug
KW - Endoplasmic Reticulum Stress/drug effects
KW - Gene Expression Profiling
KW - Hep G2 Cells
KW - Hepatocytes/drug effects
KW - Humans
KW - Liver/cytology
KW - MAP Kinase Signaling System
KW - Metabolomics
KW - NF-kappa B/genetics
KW - Signal Transduction
KW - Tandem Mass Spectrometry
UR - https://doi.org/10.1016/j.taap.2017.07.014
U2 - 10.1016/j.taap.2017.07.014
DO - 10.1016/j.taap.2017.07.014
M3 - Article
C2 - 28733206
VL - 332
SP - 100
EP - 108
JO - Toxicology and Applied Pharmacology
JF - Toxicology and Applied Pharmacology
SN - 0041-008X
ER -